Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
about
Evaluation of protein biomarkers of prostate cancer aggressivenessPreclinical and clinical development of siRNA-based therapeuticsERG is a critical regulator of Wnt/LEF1 signaling in prostate cancerThe ETS family of oncogenic transcription factors in solid tumours.STAMP2 increases oxidative stress and is critical for prostate cancer.Expression of ERG protein in prostate cancer: variability and biological correlates.Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.FGF23 promotes prostate cancer progression.Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo.Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.Recurrent gene fusions in prostate cancer: their clinical implications and uses.Liposomal siRNA nanocarriers for cancer therapy.The oncogene ERG: a key factor in prostate cancer.The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.Drug discovery in advanced prostate cancer: translating biology into therapy.Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis.Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth.Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases
P2860
Q21261257-9C5FA10A-E844-44B0-B95C-9F6E80871B31Q28085290-DF1FA697-07A0-40E6-A270-4ADC73370C96Q28771736-20EF3B04-5971-4677-8E76-CFA3CF0850F7Q34555986-34E5120E-C62B-43A0-949D-8E836A68075FQ35192455-5A222970-BCB7-4D7E-8B0B-AAE61354E235Q35608000-1F1C6738-1D49-4CDB-A47C-02DCBFCC869AQ35620225-10D62C36-50DC-45D8-86D0-9381164DF166Q36232035-D5C64D0D-738F-4DE8-9CA4-4840CF7146A0Q36354955-C9FC4D14-B1EB-4AE9-9A54-D8A7AE528693Q37054053-3E856588-7A78-457E-B0DC-5B69F656335FQ37626205-DC685FF8-053F-4EA1-B341-42813145BC68Q37660030-57600884-ABC2-42F1-8C3C-ADECAE5D7725Q37706996-B705D0EB-0D6B-42E2-B89D-20E61BF6381FQ37727814-D4C5E5DE-FD29-48A0-8F07-F504E2961034Q38102618-1B488838-0A7C-47FC-BFA4-9AB1EB1CC7B2Q38175250-188BD646-63D3-4368-903F-794DB17CA733Q38444138-A0D3BFE4-8C29-4BD3-A3F5-752951351948Q38766041-DD76CF06-926F-44BD-8921-E4431BED9E75Q38839110-941D469F-DB08-4AB0-AB96-4BCFF66C530AQ38902498-184B7F47-D4FE-45A4-9405-97A212EFAA09Q38969070-F2FAA27D-83E9-4757-8BD9-C8830736B326Q40028950-2C11F9AC-49E4-40F2-8D36-571539F87BD7Q42335698-5F3B2D45-D6A0-4902-8DE1-9A4C542E492EQ58573182-46A64523-648F-4D5F-B96B-8F8BC4808C05
P2860
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
@en
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
@nl
type
label
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
@en
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
@nl
prefLabel
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
@en
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
@nl
P2093
P2860
P1476
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
@en
P2093
Bulent Ozpolat
Erkan Yuca
Gabriel Lopez-Berestein
Ibrahim Tekedereli
Jianghua Wang
Longjiang Shao
Michael Ittmann
Susan Tsang
P2860
P304
P356
10.1158/1078-0432.CCR-12-2715
P407
P577
2012-10-10T00:00:00Z